We prescribe SPRAVATO® for management of treatment resistant depression. Dosages are dependent on the patient’s symptoms and follow a strict protocol to ensure safety and positive clinical outcomes. You will be monitored by the Midwest Alternative Treatment Clinic’s team to assure you are getting the best results. The medication is a smaller dose than IV ketamine and is often covered by commercial insurance carriers.
SPRAVATO®, also known as esketamine, is an alternative form of treatment that is becoming increasingly popular for mental health management.
SPRAVATO ® is FDA approved for the treatment of depressive symptoms with major depressive disorder (MDD) with acute suicidal ideation or behavior.
SPRAVATO® may offer several advantages over IV administration, such as ease of administration, reduced risk of adverse effects, and improved patient convenience
Patients receiving SPRAVATO® should have a stable medical condition, as SPRAVATO® can have significant cardiovascular effects. Patients with uncontrolled hypertension, congestive heart failure, or other cardiovascular conditions may not be suitable candidates for SPRAVATO® .
Patients with active psychosis or mania may not be suitable candidates for SPRAVATO® , as esketamine can exacerbate these conditions. Patients should be screened for active psychosis or mania before receiving SPRAVATO® .
Patients with active substance use disorder may not be suitable candidates for SPRAVATO® , as SPRAVATO® can have the potential for abuse and dependence. Patients should be screened for active substance use disorder before receiving SPRAVATO® .
Patients receiving SPRAVATO® should be willing to comply with the treatment plan, which may include regular monitoring, medication adjustments, and follow-up appointments. Patients should be informed of the potential risks and benefits of SPRAVATO® and should be willing to participate in shared decision-making with their healthcare provider.
SPRAVATO® can be a valuable option for mental health management in the vast majority of patients. Ideal candidates for SPRAVATO® include patients with stable medical conditions, no active psychosis or mania, no active substance use disorder, and a willingness to comply with the treatment plan. However, patients receiving SPRAVATO® should be closely monitored for potential adverse effects and advised to seek medical attention if they experience any unusual symptoms. As with all medications, the decision to use SPRAVATO® should be made on a case-by-case basis, with careful consideration of the patient’s individual needs and circumstances.
At Midwest Alternative Treatment Clinic, we work closely with our patients to create a program best suited to their needs. Always rooted in the human experience and relationships, we strive to understand where you are in your journey to wellness. Contact us today and begin your consultation if you are an ideal candidate for SPRAVATO®
Cost shouldn't stand in the way of getting the treatment you need. Spravato withMe is a cost-savings program that can assist with up to $8,150 of out-of-pocket expenses per calendar year. Depending on your out-of-network benefits and current deductible, this rebate program can drastically reduce your Spravato treatment costs. Many patients pay as little as $10 for each Spravato appointment.
SPRAVATO® is a revolutionary development in antidepressants. Anxiety, depression, PTSD, OCD, and other illnesses that used to be more challenging to address are now within sight of a fast-acting adjunct with a growing reputation in the medical community. People who use SPRAVATO® tend to experience quick symptom relief, sometimes within an hour or two.
The effects of even a single low dose of SPRAVATO® can linger for up to a week and often continue to grow much longer once a few more doses have been administered. Furthermore, significant emotional and psychological discoveries often result from the subjective impacts on consciousness and the psyche.
Cortical neurons degenerate under chronic stress. Neurons can atrophy (shrink and die) when exposed to chronically high doses of the stress hormone cortisol. Dendrites go from having many short, spreading branches that link to many neurons to having a few long, stubby branches that attach to fewer neurons. The axons attenuate and become less robust. Extreme stress can alter glutamate signaling and reduce cell responsiveness and connectivity. Imaging studies reveal a smaller prefrontal cortex in sad persons. Reduced cortical connectivity impairs the efficiency of the brain’s memory, decision-making, emotion, and focus circuits.
All these alterations in glutamate-related neurons culminate in a brain significantly more inclined to exhibit the constellation of subjective events we term depression and anxiety.
Although SPRAVATO® is known to affect other receptor types, it appears to have its greatest impact on glutamate receptors. Glutamate is a powerful neurotransmitter, known to play a part in nervous system regulation. Overstimulation of glutamate is linked to anxiety, depression, restlessness, difficulty concentrating, fatigue, and increased sensitivity to pain. At lower doses (such as those used for treatment in mental health), SPRAVATO® enhances glutamate production, which may be responsible for stimulating new neuronal connections and regenerating existing synapses.
SPRAVATO® rapidly up-regulates neuronal synthesis and release of BDNF (brain-derived neurotrophic factor) by raising the level of glutamate transmission and altering the balance of glutamate activation from NMDA to AMPA receptors. BDNF is a protein that aids in the development, maintenance, and survival of neurons; in other words, it increases neuroplasticity, hence the adage that it helps “fertilize” the brain.
SPRAVATO® also promotes the synthesis of proteins important in long-term memory by activating a major cell pathway called mTOR (mammalian target of rapamycin), which controls numerous processes related to cell growth.
Stimulating mTOR increases the production of brain-derived neurotrophic factor (BDNF), which in turn improves the hippocampus and prefrontal cortex (two brain regions crucial to emotional regulation) and reverses synaptic damage in these regions caused by chronic stress.
Precisely because of these neuroplastic effects, dendritic spine regrowth can occur within a few hours of a therapeutic dose of ketamine. Anxiety and depression symptoms subside when damaged neurons can recover and forge new connections.
SPRAVATO® appears to lose its discriminatory effect and block both NMDA and AMPA receptors at greater dosages.
Neuroplasticity and BDNF upregulation are inhibited when any or both receptor subtypes are blocked.
Perhaps this is why the antidepressant effects of ketamine weren’t discovered until recently.
Its antidepressant effect was accidentally found when researchers at Yale began using it in much lower dosages as a psychiatric treatment.
The drug has been used as a surgical anesthetic since the 1970s.
New information on how ketamine works is emerging from ongoing studies. Parvalbumin interneurons are a type of neuron that include NMDA receptors, which could be another mechanism for ketamine.
These neurons are small and uncommon but crucial in coordinating the brain’s electrical activity. They perform their function by suppressing the activity of neighboring neurons. Ketamine blocks a subunit of the NMDA receptors on these neurons, resulting in less glutamate entering the cells and a diminished inhibitory action. The parvalbumin interneurons slow down the brain’s processing speed. When you let up on the brake, activity in all regions of your brain increases. The mind becomes alert and more active.
Dopamine and noradrenaline are two of the neuromodulators ketamine can additionally stimulates. It also weakly binds to opioid and nicotinic receptors. It is still unclear, and sometimes conflicting, the specific functions these receptors have in the antidepressant action. Continued research and data collection will allow for increased understanding and increasingly better treatment options for individuals in need.
SPRAVATO® application in management of mental health, and substance use disorders has gradually become more accepted and has increased research in the area of psychedelics over the last decade. Although SPRAVATO® alone has demonstrated positive antidepressant and anxiolytic effects, current literature suggests incorporation of psychotherapy to promote an increase in success and possibly prolong the positive effects of ketamine. Building a trusting relationship with your healthcare provider and/or therapist is essential for the success of ketamine integration. Regular talk therapy sessions most frequently fulfill this need for processing and integration of insights and experiences that occur during SPRAVATO® sessions.
Regular exercise is an effective way to manage anxiety symptoms. It can help reduce stress, boost mood, and improve physical health. Exercise also releases endorphins, which are natural mood-boosting chemicals in the brain.
Sleep is essential for overall health and well-being. Aim for 7-9 hours of sleep per night and establish a regular sleep routine to promote restful sleep.
A healthy diet of fruits, vegetables, lean protein, and whole grains can help manage anxiety symptoms. Avoid or limit caffeine and alcohol, which can exacerbate anxiety symptoms.
Anxiety often involves negative thoughts that can be irrational or distorted. Challenging and replacing these thoughts with more realistic and positive ones can help manage anxiety symptoms. This technique is called cognitive restructuring.
Social support from friends, family, or support groups can help manage anxiety symptoms. Social support can provide a sense of comfort, validation, and perspective.
Mindfulness involves being present at the moment and non-judgmentally observing one's thoughts and emotions. Mindfulness-based techniques are effective in managing symptoms related to mental health and wellness.
Whether SPRAVATO® is right for you depends on various factors, including your specific medical history, the condition you are seeking treatment for, and the advice of a qualified healthcare professional. Midwest Alternative Treatment clinic will provide a thorough assessment of your individual circumstances and make appropriate recommendations.
Like any treatment, not all patients will have positive results. It’s also important to know that SPRAVATO® isn’t a cure, but rather an adjunct to improve your current therapy; it’s a better way to help you overcome your unique challenges.
Spravato (esketamine) is a prescription nasal spray used to treat treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts or behaviors. It is derived from ketamine, an anesthetic with fast-acting antidepressant effects.
Midwest Alternative Treatment Clinic follows the FDA-approved protocol, in sequence, the frequency of treatments is:
– Introduction phase: Twice weekly for 4 weeks,
– Optimization phase: Once weekly for 4 weeks,
– Maintenance phase: Once every 2 weeks
– Ongoing maintenance phase: Once every 3-4 weeks if the patients’ mood is stable
No, SPRAVATO® cannot be taken at home. Although you self-administer the nasal spray, it must be done in a certified healthcare setting under the direct supervision of a provider due to safety and monitoring requirements. cannot be taken at home.
At your SPRAVATO® appointment, you’ll check in, have your vital signs taken, and receive guidance on self-administering the nasal spray. After treatment, you’ll be monitored for about two hours to ensure safety and manage any side effects, and you’ll receive post-treatment instructions like avoiding driving. Procedures can vary by patient, so check with your provider for details.
SPRAVATO® should not be used by individuals who have a known allergy to esketamine or any of the formulation’s ingredients. Additionally, it is typically avoided in patients with uncontrolled high blood pressure, certain cardiovascular conditions, or a history of aneurysmal vascular disease or intracerebral hemorrhage. Patients with active psychosis or certain other psychiatric conditions, as well as pregnant or breastfeeding women, should consult their healthcare provider before considering Spravato. It’s essential to discuss your full medical history with your provider to determine if Spravato is safe for you.
A SPRAVATO® treatment course starts with an induction phase aimed at maximizing effectiveness. During this phase, you’ll have two treatments per week for four weeks, then one treatment per week for another four weeks. Following induction, you’ll move into a maintenance phase, where treatments are usually given every other week, though some patients may need weekly sessions based on their symptoms.
The cost of SPRAVATO® treatment can vary based on factors such as dosing frequency, treatment duration, and your insurance coverage. When insurance covers SPRAVATO®, the co-pay for a treatment session is often similar to that of a standard outpatient mental health appointment, sometimes as low as $10. However, the exact out-of-pocket cost depends on your specific insurance plan, deductible, and other factors.
SPRAVATO® is an FDA-approved nasal treatment that patients self-administer under a healthcare provider’s guidance, while IV ketamine is FDA-cleared for off-label use and must be administered directly by a healthcare provider.
We opened Midwest Alternative Treatment Clinic to improve the lives of patients who suffer from depression, anxiety, addiction, chronic pain, and PTSD.
CLOSED
9:00 AM - 6:00 PM
9:00 AM - 6:00 PM
9:00 AM - 6:00 PM
9:00 AM - 6:00 PM
9:00 AM - 6:00 PM
CLOSED
1100 Lake St. Suite 260 Oak Park, IL 60301
info@progressiveketamine.com
(708) 334-8075
We reply as soon as possible